The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | Neurological symptoms and assessing neuropathy in patients with amyloidosis
Chafic Karam, MD, University of Pennsylvania, Philadelphia, PA, shares an insight into a talk on understanding other subspecialties when treating patients with amyloidosis, focusing primarily on the neurological aspects of the disease. Patients may present with a host of neurological symptoms, from numbness and tingling (which begins in the feet and progresses to the hands) to dysautonomia-related gastrointestinal (GI) symptoms and subsequent weight loss. In his talk, Dr Karam discussed the techniques used to assess for neuropathy in the clinic and in clinical trials, as well as outlining some biomarkers whose levels may be altered by certain drugs or due to nerve damage. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
